Kymera Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $39.2 | $47.1 | $78.6 | $46.8 | $72.8 |
| Operating income | -$349.4 | -$261.6 | -$165.5 | -$161.3 | -$100.5 |
| Net income | -$311.4 | -$223.9 | -$147.0 | -$154.8 | -$100.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$234.3 | -$207.3 | -$137.3 | -$155.9 | -$130.5 |
Shares outstanding 83.2M · Free float 69.7%
Annual filing data through FY ended December 31, 2025; float as of October 5, 2026.